BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
BioRestorative Therapies (NASDAQ:BRTX) reported significant financial improvements for 2024, with total revenue increasing 175% to $401,000 from $146,000 in 2023. The company reduced its operating loss by 24% to $11.6 million and improved net loss by 14% to $9.0 million ($1.16 per share).
Key developments include:
- FDA Fast Track designation for BRTX-100 program for chronic lumbar disc disease (cLDD) treatment
- FDA clearance for BRTX-100 IND application for chronic cervical discogenic pain
- Provisional license from NY State Department of Health for allogeneic tissue processing
- Positive preliminary Phase 2 trial data for BRTX-100 showing no serious adverse events
The company ended 2024 with $10.7 million in cash and investments, with no outstanding debt. BioCosmeceuticals generated $300,000 in revenue for 2024.
BioRestorative Therapies (NASDAQ:BRTX) ha riportato significativi miglioramenti finanziari per il 2024, con un aumento del fatturato totale del 175%, passando da $146.000 nel 2023 a $401.000. L'azienda ha ridotto la propria perdita operativa del 24%, raggiungendo $11,6 milioni, e ha migliorato la perdita netta del 14%, portandola a $9,0 milioni ($1,16 per azione).
Sviluppi chiave includono:
- Designazione Fast Track da parte della FDA per il programma BRTX-100 per il trattamento della malattia discale lombare cronica (cLDD)
- Autorizzazione della FDA per l'applicazione IND di BRTX-100 per il dolore discogeno cervicale cronico
- Licenza provvisoria dal Dipartimento della Salute dello Stato di New York per la lavorazione di tessuti allogenici
- Dati preliminari positivi della Fase 2 per BRTX-100 che mostrano nessun evento avverso grave
L'azienda ha concluso il 2024 con $10,7 milioni in contante e investimenti, senza debiti in sospeso. BioCosmeceuticals ha generato $300.000 di fatturato per il 2024.
BioRestorative Therapies (NASDAQ:BRTX) reportó mejoras financieras significativas para el 2024, con un aumento del 175% en los ingresos totales, alcanzando $401,000 desde $146,000 en 2023. La compañía redujo su pérdida operativa en un 24%, alcanzando los $11.6 millones, y mejoró su pérdida neta en un 14%, llevándola a $9.0 millones ($1.16 por acción).
Los desarrollos clave incluyen:
- Designación de Fast Track por la FDA para el programa BRTX-100 para el tratamiento de la enfermedad discal lumbar crónica (cLDD)
- Aprobación de la FDA para la aplicación IND de BRTX-100 para el dolor discogénico cervical crónico
- Licencia provisional del Departamento de Salud del Estado de Nueva York para el procesamiento de tejidos alogénicos
- Datos preliminares positivos del ensayo de Fase 2 para BRTX-100 que muestran ningún evento adverso grave
La compañía terminó el 2024 con $10.7 millones en efectivo e inversiones, sin deudas pendientes. BioCosmeceuticals generó $300,000 en ingresos para el 2024.
BioRestorative Therapies (NASDAQ:BRTX)는 2024년 재무 개선이 크게 이루어졌다고 보고했으며, 총 수익이 2023년 $146,000에서 $401,000으로 175% 증가했습니다. 회사는 운영 손실을 24% 줄여 $11.6 백만에 도달했으며, 순손실을 14% 개선하여 $9.0 백만($1.16 주당)으로 줄였습니다.
주요 개발 사항은 다음과 같습니다:
- 만성 요추 디스크 질환(cLDD) 치료를 위한 BRTX-100 프로그램의 FDA 패스트 트랙 지정
- 만성 경추 디스크 통증에 대한 BRTX-100 IND 신청의 FDA 승인
- 알로겐 조직 가공을 위한 뉴욕주 보건부의 임시 라이센스
- BRTX-100에 대한 긍정적인 2상 시험 데이터, 심각한 부작용이 없음
회사는 2024년을 $10.7 백만의 현금 및 투자로 마감했으며, 미지급 부채가 없습니다. BioCosmeceuticals는 2024년 동안 $300,000의 수익을 창출했습니다.
BioRestorative Therapies (NASDAQ:BRTX) a rapporté des améliorations financières significatives pour 2024, avec un chiffre d'affaires total en hausse de 175 %, atteignant 401 000 $ contre 146 000 $ en 2023. L'entreprise a réduit sa perte d'exploitation de 24 %, pour atteindre 11,6 millions de dollars, et a amélioré sa perte nette de 14 %, la portant à 9,0 millions de dollars (1,16 $ par action).
Les développements clés incluent :
- Désignation Fast Track par la FDA pour le programme BRTX-100 pour le traitement de la maladie discale lombaire chronique (cLDD)
- Approbation de la FDA pour la demande IND de BRTX-100 pour la douleur discogène cervicale chronique
- Licence provisoire du Département de la santé de l'État de New York pour le traitement des tissus allogéniques
- Données préliminaires positives de l'essai de phase 2 pour BRTX-100 montrant aucun événement indésirable grave
L'entreprise a terminé 2024 avec 10,7 millions de dollars en liquidités et investissements, sans dettes en cours. BioCosmeceuticals a généré 300 000 $ de revenus pour 2024.
BioRestorative Therapies (NASDAQ:BRTX) berichtete über signifikante finanzielle Verbesserungen für 2024, wobei die Gesamteinnahmen um 175% auf $401.000 von $146.000 im Jahr 2023 stiegen. Das Unternehmen reduzierte seinen operativen Verlust um 24% auf $11,6 Millionen und verbesserte den Nettoverlust um 14% auf $9,0 Millionen ($1,16 pro Aktie).
Wichtige Entwicklungen umfassen:
- FDA Fast Track-Bezeichnung für das BRTX-100-Programm zur Behandlung von chronischer lumbaler Bandscheibenerkrankung (cLDD)
- FDA-Freigabe für den BRTX-100 IND-Antrag bei chronischen zervikalen diskogenen Schmerzen
- Vorläufige Lizenz des Gesundheitsministeriums des Bundesstaates New York für die Verarbeitung von allogenen Geweben
- Positive vorläufige Phase-2-Studienergebnisse für BRTX-100, die keine schwerwiegenden unerwünschten Ereignisse zeigen
Das Unternehmen schloss das Jahr 2024 mit $10,7 Millionen in bar und Investitionen ab, ohne ausstehende Schulden. BioCosmeceuticals erzielte im Jahr 2024 Einnahmen in Höhe von $300.000.
- 175% revenue growth to $401,000 in 2024
- 24% reduction in operating loss to $11.6 million
- Strong cash position of $10.7 million with zero debt
- FDA Fast Track designation for BRTX-100
- Positive Phase 2 trial data with no serious adverse events
- Expanded BRTX-100 pipeline to include neck pain treatment
- Substantial net loss of $9.0 million despite improvements
- revenue base of $401,000 despite growth
- High cash burn with $8.2 million used in operating activities
Insights
BioRestorative's 2024 results show meaningful financial improvement despite remaining in early commercial stages. Revenue jumped
The company's
While the revenue base remains modest relative to operating expenses, the improving financial metrics during a period of clinical advancement suggest responsible cash management. The current market capitalization of approximately
The FDA Fast Track designation for BRTX-100 represents a significant regulatory milestone that could accelerate development timelines and increase probability of success. This designation, based on preliminary Phase 2 data, validates the therapeutic potential for chronic lumbar disc disease (cLDD) and potentially unlocks Priority Review and Accelerated Approval pathways.
The blinded 26-52 week data from the first 15 patients demonstrates three critical elements: safety (no serious adverse events), potential efficacy (improved VAS/ODI scores), and possible disease modification (MRI changes showing increased hydration, decreased protrusion size, and resolution of annular tears). These MRI findings are particularly noteworthy as they suggest actual structural improvement rather than merely masking pain symptoms.
The FDA's clearance of the IND for chronic cervical discogenic pain substantially expands the addressable market potential. The NYSDOH provisional license for allogeneic tissue processing provides necessary infrastructure for scaling production capabilities.
Ongoing discussions regarding the ThermoStem metabolic platform represent a secondary value driver, though timelines remain undefined. The company's strategic focus on regenerative stem cell therapies for major markets with unmet needs positions them well, provided the full Phase 2 dataset confirms these preliminary positive signals.
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business.
“2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progress.”
Recent Highlights
DEVELOPMENT
- In November, BioRestorative received a provisional license from the New York State Department of Health (“NYSDOH”) for the processing of allogeneic (non-autologous) donor tissue material for the isolation, expansion and cryopreservation of various cell types, including stem cells, for medical research. Previously, the Company was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from autologous donors only.
Disc/Spine Program
- In a podium presentation at the 2025 Orthopaedic Research Society (“ORS”) Annual Meeting in February, the Company’s Vice President of Research and Development, Francisco Silva, presented 26–52 week blinded data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100. No serious adverse events (SAEs) were reported, and there was no dose (40X106 cells) limiting toxicity at 26-52 weeks. Preliminary blinded Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) data collected at weeks 26 and 52 post-injection demonstrated an exceptionally positive trend compared to baseline. Furthermore, 52 week comparison of MRI images to baseline appear to demonstrate morphological changes, such as an increase in T2 signal (hydration), a decrease in protrusion size, as well as resolutions of annular tears, potentially demonstrating disc microenvironment remodeling as a result of cLDD treatment with BRTX-100.
- On the heels of the ORS presentation, BioRestorative announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation to the BRTX-100 program for the treatment of cLDD. Fast Track designation reflects the positive preliminary Phase 2 safety and efficacy data reported to date. The Company hopes that such designation will lead to Priority Review and Accelerated Biologics License Application (BLA) Approval for BRTX-100.
- Also in February, the FDA cleared the Company’s Investigational New Drug (“IND”) application for BRTX-100 for the treatment of chronic cervical discogenic pain (cCDP), expanding BioRestorative’s advanced clinical pipeline for BRTX-100 to include the treatment of both chronic lower back and neck pain.
Metabolic Program
- The Company’s previously reported substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a potential license of BioRestorative’s ThermoStem® metabolic intellectual property are continuing; however, no assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise.
- BioRestorative also continues to explore a first-in-human clinical trial for its ThermoStem® metabolic platform technology.
COMMERCIAL
BioCosmeceuticals
- The Company derived
$300,000 in revenue from BioCosmeceuticals in 2024.
Summary 2024 Results
Total revenue for the year ended December 31, 2024 was
The Company’s 2024 loss from operations was
The Company’s 2024 net loss was
Cash used in operating activities in 2024 was
The Company ended the year in a strong financial position, with cash, cash equivalents, and investments held in marketable securities of
For complete financial results, please see BioRestorative’s filings at www.sec.gov, and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
Conference Call Details
BioRestorative management will host a webcasted conference call with an associated slide presentation today at 4:30pm EDT to review its 2024 financial results and provide a business update. To join the conference call via telephone and participate in the live Q&A session, please dial 888-506-0062 (United States) or 973-528-0011 (International), participant access code 726526. The call will also be webcast live and archived on the investor section of the Company’s website at www.biorestorative.com under “Events”’ in the Investors and Media section.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured as a third party contract manufacturer, using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
